Abstract
Chronic inflammatory disorders constitute a heterogenous group of complex and multifactorial diseases, which are often associated with increased cardiovascular morbidity and mortality, independent of the established cardiovascular risk factors. In keeping with this observation, hypercoagulability is frequently observed in patients suffering from atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis although the physiological significance of activated coagulation remained elusive. However, the identification of protease activated receptors (PAR) seems to provide a link between coagulation activation and disease progression as their activation by coagulation factors triggers a broad range of signaling pathways relevant for chronic inflammatory disorders. In experimental animal models, anticoagulation and/or genetic ablation of PAR signaling affords protection against the perpetuation of atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis. It is thus tempting to speculate that targeting the coagulation-PAR axis might have clinical relevance in the setting of chronic inflammatory disorders. In the current review, we discuss the current knowledge on coagulation activation in inflammatory disorders, we discuss the relationship between atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis and we review the current knowledge on PAR signaling in these disorders.
Keywords: Chronic inflammatory disorders, coagulation, inflammation, protease-activated receptors, atherosclerosis, chronic obstructive pulmonary diseas, rheumatoid arthritis, maresins, inter alia, eicosapen-taenoic acid, n-3, ApoE4 genotype, rotoxins, methylmercury, microcephaly, cerebral palsy, institutional boilers, chlo-rine production, waste incineration, oceans - bio-concentrate, sporadic, vitro nitrosamine, neurodegeneration, cadaverine, biogenic amine, amyloid, beta amyloid, amy-loidosis, DHA-oxygenation pathways, ASA-generated, acetylating COX-2, COX, arachidonic acid (ARA), resolvins, protect-ins, neuroprotectin D1 (NPD1, neurite growth, A pep-tide, brain-derived neurotrophic factor, superoxide dismutase-1, catalase, Reactive oxygen species, catecholamine synthesis, n-3 family, PUFAs, glial cells, astro-cytes, BDNF protein
Current Pharmaceutical Design
Title: The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades
Volume: 17 Issue: 1
Author(s): Keren S. Borensztajn, Jan H. von der Thusen and C. Arnold Spek
Affiliation:
Keywords: Chronic inflammatory disorders, coagulation, inflammation, protease-activated receptors, atherosclerosis, chronic obstructive pulmonary diseas, rheumatoid arthritis, maresins, inter alia, eicosapen-taenoic acid, n-3, ApoE4 genotype, rotoxins, methylmercury, microcephaly, cerebral palsy, institutional boilers, chlo-rine production, waste incineration, oceans - bio-concentrate, sporadic, vitro nitrosamine, neurodegeneration, cadaverine, biogenic amine, amyloid, beta amyloid, amy-loidosis, DHA-oxygenation pathways, ASA-generated, acetylating COX-2, COX, arachidonic acid (ARA), resolvins, protect-ins, neuroprotectin D1 (NPD1, neurite growth, A pep-tide, brain-derived neurotrophic factor, superoxide dismutase-1, catalase, Reactive oxygen species, catecholamine synthesis, n-3 family, PUFAs, glial cells, astro-cytes, BDNF protein
Abstract: Chronic inflammatory disorders constitute a heterogenous group of complex and multifactorial diseases, which are often associated with increased cardiovascular morbidity and mortality, independent of the established cardiovascular risk factors. In keeping with this observation, hypercoagulability is frequently observed in patients suffering from atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis although the physiological significance of activated coagulation remained elusive. However, the identification of protease activated receptors (PAR) seems to provide a link between coagulation activation and disease progression as their activation by coagulation factors triggers a broad range of signaling pathways relevant for chronic inflammatory disorders. In experimental animal models, anticoagulation and/or genetic ablation of PAR signaling affords protection against the perpetuation of atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis. It is thus tempting to speculate that targeting the coagulation-PAR axis might have clinical relevance in the setting of chronic inflammatory disorders. In the current review, we discuss the current knowledge on coagulation activation in inflammatory disorders, we discuss the relationship between atherosclerosis, chronic obstructive pulmonary disease and rheumatoid arthritis and we review the current knowledge on PAR signaling in these disorders.
Export Options
About this article
Cite this article as:
S. Borensztajn Keren, H. von der Thusen Jan and Arnold Spek C., The Role of Coagulation in Chronic Inflammatory Disorders: A Jack of All Trades, Current Pharmaceutical Design 2011; 17 (1) . https://dx.doi.org/10.2174/138161211795049813
DOI https://dx.doi.org/10.2174/138161211795049813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Small Molecule Inhibitors of PKCθ as Potential Antiinflammatory Therapeutics
Current Topics in Medicinal Chemistry Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Rheumatoid Arthritis and Cardiovascular Risk: Between Lights and Shadows
Current Rheumatology Reviews Carrier Mediated Systemic Delivery of Protein and Peptide Therapeutics
Current Pharmaceutical Design Potent Inhibitory Effects of Quercetin on Inflammatory Responses of Collagen-Induced Arthritis in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Ex-ante Evaluation of Biotechnology Innovations: the Case of Folate Biofortified Rice in China
Current Pharmaceutical Biotechnology Anti Citrullinated Protein Antibodies and Mechanism of Action of Common Disease Modifying Drugs - Insights in Pathomechanisms of Autoimmunity
Current Pharmaceutical Design Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Evaluating the Effect of Oral N-acetylcysteine as an Adjuvant Treatment on Clinical Outcomes of Patients with Rheumatoid Arthritis: A Randomized, Double Blind Clinical Trial
Reviews on Recent Clinical Trials Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Folate Receptor Targeted Liposomes
Drug Design Reviews - Online (Discontinued) Lipid based Nanocarriers for Oral Delivery of Cancer Chemotherapeutics: An Insight in the Intestinal Lymphatic Transport
Drug Delivery Letters